Vericel’s High Growth Trajectory Has Staying Power

Vericel's MACI orthobiologic

Vericel reported 4Q19 orthopedic revenue of USD $33.6 million, +33.8% vs. 4Q18, with full-year 2019 revenue of $91.6 million, +35.3% vs. 2018. In 2019, the company received biopsies from nearly 1,400 surgeons representing about a quarter of Vericel’s estimated target market and a 25% increase over 2018. To capitalize on the growing...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us